Fresenius Medical Care AG & Co. KGaA (FMEA) - Net Assets
Based on the latest financial reports, Fresenius Medical Care AG & Co. KGaA (FMEA) has net assets worth €14.28 Billion EUR (≈ $16.70 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€31.00 Billion ≈ $36.24 Billion USD) and total liabilities (€16.72 Billion ≈ $19.55 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FMEA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €14.28 Billion |
| % of Total Assets | 46.07% |
| Annual Growth Rate | 3.06% |
| 5-Year Change | 2.17% |
| 10-Year Change | N/A |
| Growth Volatility | 9.11 |
Fresenius Medical Care AG & Co. KGaA - Net Assets Trend (2016–2025)
This chart illustrates how Fresenius Medical Care AG & Co. KGaA's net assets have evolved over time, based on quarterly financial data. Also explore FMEA total assets for the complete picture of this company's asset base.
Annual Net Assets for Fresenius Medical Care AG & Co. KGaA (2016–2025)
The table below shows the annual net assets of Fresenius Medical Care AG & Co. KGaA from 2016 to 2025. For live valuation and market cap data, see FMEA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €14.28 Billion ≈ $16.70 Billion |
-9.42% |
| 2024-12-31 | €15.77 Billion ≈ $18.44 Billion |
+6.35% |
| 2023-12-31 | €14.83 Billion ≈ $17.33 Billion |
-4.03% |
| 2022-12-31 | €15.45 Billion ≈ $18.06 Billion |
+10.52% |
| 2021-12-31 | €13.98 Billion ≈ $16.34 Billion |
+13.36% |
| 2020-12-31 | €12.33 Billion ≈ $14.42 Billion |
-6.77% |
| 2019-12-31 | €13.23 Billion ≈ $15.46 Billion |
+2.52% |
| 2018-12-31 | €12.90 Billion ≈ $15.08 Billion |
+19.15% |
| 2017-12-31 | €10.83 Billion ≈ $12.66 Billion |
-0.60% |
| 2016-12-31 | €10.89 Billion ≈ $12.74 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fresenius Medical Care AG & Co. KGaA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 100.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €12.21 Billion | 91.72% |
| Other Components | €1.10 Billion | 8.28% |
| Total Equity | €13.31 Billion | 100.00% |
Fresenius Medical Care AG & Co. KGaA Competitors by Market Cap
The table below lists competitors of Fresenius Medical Care AG & Co. KGaA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GAIL (India) Limited
NSE:GAIL
|
$11.61 Billion |
|
CENTRICA ADR NEW 2004/4
F:CENN
|
$11.61 Billion |
|
Guangxi Guiguan Electric Power Co Ltd
SHG:600236
|
$11.64 Billion |
|
NortonLifeLock Inc
F:SYM
|
$11.65 Billion |
|
China Aerospace Times Electronics Co Ltd
SHG:600879
|
$11.57 Billion |
|
Solventum Corp.
NYSE:SOLV
|
$11.56 Billion |
|
Hyundai Glovis
KO:086280
|
$11.54 Billion |
|
Chongqing Changan Automobile Co Ltd
SHE:000625
|
$11.53 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fresenius Medical Care AG & Co. KGaA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,576,563,000 to 13,309,832,000, a change of -1,266,731,000 (-8.7%).
- Net income of 978,367,000 contributed positively to equity growth.
- Dividend payments of 422,515,000 reduced retained earnings.
- Share repurchases of 585,285,000 reduced equity.
- Other factors decreased equity by 1,237,298,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €978.37 Million | +7.35% |
| Dividends Paid | €422.51 Million | -3.17% |
| Share Repurchases | €585.28 Million | -4.4% |
| Other Changes | €-1.24 Billion | -9.3% |
| Total Change | €- | -8.69% |
Book Value vs Market Value Analysis
This analysis compares Fresenius Medical Care AG & Co. KGaA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.39x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.59x to 0.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €32.04 | €18.80 | x |
| 2018-12-31 | €38.32 | €18.80 | x |
| 2019-12-31 | €40.08 | €18.80 | x |
| 2020-12-31 | €38.29 | €18.80 | x |
| 2021-12-31 | €47.71 | €18.80 | x |
| 2022-12-31 | €52.65 | €18.80 | x |
| 2023-12-31 | €46.42 | €18.80 | x |
| 2024-12-31 | €49.68 | €18.80 | x |
| 2025-12-31 | €47.66 | €18.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fresenius Medical Care AG & Co. KGaA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.35%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.98%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 2.33x
- Recent ROE (7.35%) is below the historical average (8.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 11.50% | 6.94% | 0.66x | 2.49x | €154.41 Million |
| 2017 | 13.03% | 7.20% | 0.74x | 2.45x | €297.78 Million |
| 2018 | 16.86% | 11.98% | 0.63x | 2.23x | €806.08 Million |
| 2019 | 10.03% | 6.86% | 0.53x | 2.75x | €3.83 Million |
| 2020 | 10.38% | 6.52% | 0.56x | 2.83x | €42.87 Million |
| 2021 | 6.93% | 5.50% | 0.51x | 2.46x | €-428.90 Million |
| 2022 | 4.36% | 3.47% | 0.54x | 2.31x | €-871.90 Million |
| 2023 | 3.66% | 2.57% | 0.57x | 2.49x | €-863.03 Million |
| 2024 | 3.69% | 2.78% | 0.58x | 2.30x | €-919.74 Million |
| 2025 | 7.35% | 4.98% | 0.63x | 2.33x | €-352.62 Million |
Industry Comparison
This section compares Fresenius Medical Care AG & Co. KGaA's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $5,311,969,950
- Average return on equity (ROE) among peers: -83.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA (FMEA) | €14.28 Billion | 11.50% | 1.17x | $11.58 Billion |
| China Resources Medical Holdings Company Limited (1PH) | $7.01 Billion | 3.67% | 0.95x | $428.88 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $-125.88 Million | 0.00% | 0.00x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $10.35 Billion | 2.73% | 0.45x | $720.78 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.34 Billion | 4.88% | 1.24x | $19.18 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $24.10 Billion | 29.08% | 0.21x | $49.31K |
| Eifelhöhen-Klinik AG (EIF) | $9.88 Million | -19.11% | 6.64x | $8.99 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $2.01 Billion | -12.28% | 1.84x | $12.02 Billion |
| Fresenius SE & Co. KGaA (FRE) | $3.10 Billion | 10.64% | 3.84x | $27.16 Billion |
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arr… Read more